Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.
about
Current understanding of interactions between nanoparticles and the immune systemDynamic models of viral replication and latencyImpact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damageCD8 T cell persistence in treated HIV infectionHIV and aging: emerging research issuesRenal epithelial cells produce and spread HIV-1 via T-cell contactVisualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging.The Dynamics of T and B Cells in Lymph Node during Chronic HIV Infection: TFH and HIV, Unhappy Dance Partners?Changes in Follicular CD4+ T Helper Cells as a Marker for Evaluating Disease Progression in the Competition between HIV and Host ImmunityUsing animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence researchImpact of Chronic HIV/SIV Infection on T Follicular Helper Cell Subsets and Germinal Center HomeostasisBioinformatics and HIV latency.The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trialsOptimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor SettingsModeling the Slow CD4+ T Cell Decline in HIV-Infected IndividualsResidual Viremia in Treated HIV+ IndividualsEffects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialEfficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdAPredicting the outcomes of treatment to eradicate the latent reservoir for HIV-1Recent Insights into the HIV/AIDS Pandemic.A comparison of elasticities of viral levels to specific immune response mechanisms in human immunodeficiency virus infection.A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFH Cell Reservoir and Proposing Strategies to Overcome the Follicle SanctuaryAntiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.Immunologic strategies for HIV-1 remission and eradication.A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients.No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trialHIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection.Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies.Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individualsHIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells.Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.Progress toward curing HIV infections with hematopoietic stem cell transplantation.Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticlesLarge number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.Role of myeloid cells in HIV-1-host interplay.Eradicating HIV-1 infection: seeking to clear a persistent pathogen.Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirsAntiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia.
P2860
Q26345204-43D01CC1-13ED-4F5B-B7D2-E164D86D9044Q26866136-38FDEF07-E429-452E-9965-C86883810601Q27014077-50BD6CB2-27BC-4C54-9FBF-CE01CB31FEA0Q27014768-67327B69-5A6E-43F0-A182-1F99033308DEQ27016011-DF457802-7C82-4F39-A18C-B54A8DE0200DQ27313558-9D801909-8A9F-4524-95BC-1B76E2764D72Q27323244-841F3C38-D4A2-41D5-9DB5-3214A248F724Q28067520-E7E680CB-7448-45C0-A074-2822337F8615Q28075718-ADCDF853-8349-4C27-838C-4DF041CB3159Q28077662-E498B96A-1EE2-4249-8D17-2FE5E86B466FQ28077701-285798A6-A8E9-4FE2-A9B3-4D87014FCEEBQ28081427-1020A363-E4B7-46C2-8809-D823786D562FQ28087336-A7C10630-1A49-4C49-BD17-FDFECA4A766CQ28547109-2B0670D9-AD1B-4F94-BACA-552FC9441FA0Q28551803-DA4C1408-0D3B-4490-B870-3C4B79D96C18Q28552126-EC7B59A0-BE3F-4B9B-A104-EFA60D4C1E3FQ28552729-702423DA-F2D4-4385-8B06-07EBD14D6C21Q28552730-CFE7CCC8-327F-4B96-B936-4012EA21A72CQ28655602-0CE7AA5F-198B-4011-BBBD-FC549F06C976Q30235024-36D9B5BD-A530-4F34-9FC2-96BF161590E1Q30596957-9C1D7FFB-9F65-4FDB-98F8-04B0760ED0DCQ33728690-A6E1DA36-F0C2-4CDE-8C34-4BC4D271FB6FQ33742139-344F25D4-1737-450B-A438-436743064FFAQ33867299-EAB2C0B0-A22A-4B92-86EA-E7F35AB8CA99Q33896523-204772C3-3E94-4BF8-BE0F-A8CFDEC16404Q33911247-612AB479-CA7F-4035-8D7A-A6DA5A872455Q34450075-336B7283-1B8B-425C-970E-9651E5898F73Q34502840-5321F2AD-CB64-4BEA-B2E5-BCB740187F47Q34593784-8A3F5D9B-B396-4B20-B0C4-F5F7FF2FAD8DQ34596417-A3F355F5-7CB8-46EC-A6FD-62AC2DACD70EQ34612385-D1ECC72B-BC08-4B1F-90C3-AA36D8578AE0Q34669697-C82CDCEF-8CB8-4EC6-80F6-BA9248FDE7ADQ34869449-1E31B304-4542-4BC5-B83C-FC9766E481CBQ34974480-257B064E-C0D5-4521-90CB-7F2690CEE69CQ35147145-17488784-6D3C-417B-96AB-620291B74B50Q35190018-B8473DD1-A740-4AC2-A429-B6D5962041B4Q35196505-5B68C9FB-43CE-4E99-8A3D-55C0E70BA187Q35252186-3F22FB26-FD04-450B-8ECB-B88FC0A088E0Q35385971-97577E1B-548E-44A9-8B04-E744B7B85DB3Q35408114-9763E780-87C6-4DD9-B6AF-1D2DD9A648C7
P2860
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Persistent HIV-1 replication i ...... trations in lymphatic tissues.
@en
Persistent HIV-1 replication i ...... trations in lymphatic tissues.
@nl
type
label
Persistent HIV-1 replication i ...... trations in lymphatic tissues.
@en
Persistent HIV-1 replication i ...... trations in lymphatic tissues.
@nl
prefLabel
Persistent HIV-1 replication i ...... trations in lymphatic tissues.
@en
Persistent HIV-1 replication i ...... trations in lymphatic tissues.
@nl
P2093
P2860
P50
P356
P1476
Persistent HIV-1 replication i ...... trations in lymphatic tissues.
@en
P2093
Ann Thorkelson
Ashley T Haase
Cavan Reilly
Courtney V Fletcher
Daniel C Douek
Jodi Anderson
Katherine Perkey
Kathryn Staskus
Mario Stevenson
Meghan Rothenberger
P2860
P304
P356
10.1073/PNAS.1318249111
P407
P577
2014-01-27T00:00:00Z